Show simple item record

dc.contributor.authorMöller, Jana C
dc.contributor.authorCron, Randy Q
dc.contributor.authorYoung, Daniel W
dc.contributor.authorGirschick, Hermann J
dc.contributor.authorLevy, Deborah M
dc.contributor.authorSherry, David D
dc.contributor.authorKukita, Akiko
dc.contributor.authorSaijo, Kaoru
dc.contributor.authorPessler, Frank
dc.date.accessioned2017-06-16T08:07:40Z
dc.date.available2017-06-16T08:07:40Z
dc.date.issued2011-02-01en
dc.identifier.citationPediatric Rheumatology. 2011 Feb 01;9(1):5en
dc.identifier.urihttp://dx.doi.org/10.1186/1546-0096-9-5en
dc.identifier.urihttp://hdl.handle.net/10033/620955
dc.description.abstractAbstract Spinal epidural lipomatosis is a rare complication of chronic corticosteroid treatment. We report a new pediatric case and an analysis of this and 19 pediatric cases identified in the international literature. The youngest of these combined 20 patients was 5 years old when lipomatosis was diagnosed. Lipomatosis manifested after a mean of 1.3 (+/- 1.5) years (SD) (median, 0.8 years; range, 3 weeks - 6.5 years) of corticosteroid treatment. The corticosteroid dose at the time of presentation of the lipomatosis ranged widely, between 5 and 80 mg of prednisone/day. Back pain was the most common presenting symptom. Imaging revealed that lipomatosis almost always involved the thoracic spine, extending into the lumbosacral region in a subset of patients. Predominantly lumbosacral involvement was documented in only two cases. Although a neurological deficit at presentation was documented in about half of the cases, surgical decompression was not performed in the cases reported after 1996. Instead, reducing the corticosteroid dose (sometimes combined with dietary restriction to mobilize fat) sufficed to induce remission. In summary, pediatric spinal epidural lipomatosis remains a potentially serious untoward effect of corticosteroid treatment, which, if recognized in a timely manner, can have a good outcome with conservative treatment.
dc.titleCorticosteroid-induced spinal epidural lipomatosis in the pediatric age group: report of a new case and updated analysis of the literatureen
dc.typeJournal Articleen
dc.language.rfc3066enen
dc.rights.holderMöller et al; licensee BioMed Central Ltd.en
dc.date.updated2015-09-04T08:24:15Zen
refterms.dateFOA2018-06-13T04:14:28Z
html.description.abstractAbstract Spinal epidural lipomatosis is a rare complication of chronic corticosteroid treatment. We report a new pediatric case and an analysis of this and 19 pediatric cases identified in the international literature. The youngest of these combined 20 patients was 5 years old when lipomatosis was diagnosed. Lipomatosis manifested after a mean of 1.3 (+/- 1.5) years (SD) (median, 0.8 years; range, 3 weeks - 6.5 years) of corticosteroid treatment. The corticosteroid dose at the time of presentation of the lipomatosis ranged widely, between 5 and 80 mg of prednisone/day. Back pain was the most common presenting symptom. Imaging revealed that lipomatosis almost always involved the thoracic spine, extending into the lumbosacral region in a subset of patients. Predominantly lumbosacral involvement was documented in only two cases. Although a neurological deficit at presentation was documented in about half of the cases, surgical decompression was not performed in the cases reported after 1996. Instead, reducing the corticosteroid dose (sometimes combined with dietary restriction to mobilize fat) sufficed to induce remission. In summary, pediatric spinal epidural lipomatosis remains a potentially serious untoward effect of corticosteroid treatment, which, if recognized in a timely manner, can have a good outcome with conservative treatment.


Files in this item

Thumbnail
Name:
12969_2010_Article_805.pdf
Size:
388.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record